Top advances of the year: The status of chimeric antigen receptor T cells in neuro‐oncology
Numerous major advances have been made in the past year regarding chimeric antigen receptor (CAR) T‐cell therapy in neuro‐oncology. Disialoganglioside GD2 CAR T cells, bivalent CAR T cells, and CARv3–engineered T cells expressing a T‐cell–engaging antibody molecule all show promise for diffuse midline glioma and glioblastoma.
Authors
- Michael Lim (ORCID: https://orcid.org/0000-0003-0523-3076)
- Ethan Schonfeld (ORCID: https://orcid.org/0000-0001-7633-0450)
- Ravi Medikonda
- Matthew Abikenari (ORCID: https://orcid.org/0000-0001-5835-5179)
Institutions
- Stanford University (US)
Publication Details
- Journal
- Cancer
- Published
- 2025-06-08
- DOI
- https://doi.org/10.1002/cncr.35935
- Citations
- 7
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 7.32